Summit Partners Public Asset Management, LLC Eli Lilly & CO Call Options Transaction History

Summit Partners Public Asset Management, LLC

$2.79 Billion
Q3 2024

Call Options

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$592.2 - $792.28 $23.7 Million - $31.7 Million	40,000 New	40,000 $31.1 Million
Q4 2017 Feb 14, 2018	SELL	$81.94 - $87.89 $4.1 Million - $4.39 Million	-50,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$77.07 - $85.54 $3.85 Million - $4.28 Million	50,000	50,000 $4.28 Million

Others Institutions Holding LLY

# of Institutions

4,031

Shares Held

739M

Call Options Held

8.27M

Put Options Held

10.5M

Lilly Endowment Inc Indianapolis, IN

96.9M
Shares

$74.3 Billion
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

73.8M
Shares

$56.6 Billion
1.2% of portfolio
Black Rock Inc. New York, NY

65.9M
Shares

$50.5 Billion
1.37% of portfolio
Pnc Financial Services Group, Inc. Pittsburgh, PA

51.4M
Shares

$39.4 Billion
29.2% of portfolio
State Street Corp Boston, MA

33.9M
Shares

$26 Billion
1.24% of portfolio

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $728B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Partners Public Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Summit Partners Public Asset Management, LLC with notifications on news.

Account